Feline Immunodeficiency Virus (FIV) is a lentivirus that infects domestic cats and other feline species, leading to an immunodeficiency syndrome similar to human immunodeficiency virus (HIV) infection in humans. The management and treatment of FIV are essential to improve the quality of life and longevity of infected cats. Antiviral drugs have been investigated as potential treatment options for FIV, aiming to inhibit viral replication and disease progression. This study aims to assess the efficacy of antiviral drugs against FIV through in vitro and in vivo experiments. In vitro studies involved testing the antiviral activity of various drugs against FIV-infected feline cell cultures. In vivo evaluations were performed using FIV-infected cats, administering the selected antiviral drugs and monitoring viral load, clinical symptoms, and immunological parameters. The results offer critical insights into the effectiveness of different antiviral drugs and their potential for managing FIV in domestic cats.
Gleich, S.E.; Krieger, S.; Hartmann, K. Prevalence of feline immunodeficiency virus and feline leukaemia virus among client-owned cats and risk factors for infection in germany. J. Feline Med. Surg. 2009, 11, 985–992. [Google Scholar] [CrossRef] [PubMed]
Addie, D.D.; Dennis, J.M.; Toth, S.; Callanan, J.J.; Reid, S.; Jarrett, O. Long-term impact on a closed household of pet cats of natural infection with feline coronavirus, feline leukaemia virus and feline immunodeficiency virus. Vet. Rec. 2000, 146, 419–424. [Google Scholar] [CrossRef] [PubMed]
Levy, J.; Crawford, C.; Hartmann, K.; Hofmann-Lehmann, R.; Little, S.; Sundahl, E.; Thayer, V. 2008 american association of feline practitioners’ feline retrovirus management guidelines. J. Feline Med. Surg. 2008, 10, 300–316. [Google Scholar] [CrossRef] [PubMed]
De Clercq, E. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491–2517. [Google Scholar] [CrossRef] [PubMed]
De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 2009, 33, 307–320. [Google Scholar] [CrossRef] [PubMed]
Hartmann, K. Antiviral and immunomodulatory chemotherapy. In Infectious Diseases of the Dog and Cat, 4th ed.; Greene, C.E., Ed.; Elsevier, Saunders: St Louis, MO, USA, 2012; pp. 10–24. [Google Scholar]
Auwerx, J.; Esnouf, R.; de Clercq, E.; Balzarini, J. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors. Mol. Pharmacol. 2004, 65, 244–251. [Google Scholar] [CrossRef] [PubMed]
Mohammadi, H.; Bienzle, D. Pharmacological inhibition of feline immunodeficiency virus (FIV). Viruses 2012, 4, 708–724. [Google Scholar] [CrossRef] [PubMed]
Tressler, R.; Godfrey, C. NRTI backbone in HIV treatment: Will it remain relevant? Drugs 2012, 72, 2051–2062. [Google Scholar] [CrossRef] [PubMed]
De Clercq, E. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS). Adv. Pharmacol. 2013, 67, 317–358. [Google Scholar] [PubMed]